Cue Biopharma to host virtual investor event

Cue Biopharma (CUE) announced that it will host a virtual investor event on Thursday, May 15, 2025 at 11:00 AM ET. To register, click here. The virtual event will feature key opinion leaders Richard DiPaolo, PhD and Andrew Cope, MD, PhD. Together with Cue Biopharma’s management, they will discuss the Company’s differentiated biologics platform, which has the unique potential to selectively activate and expand disease relevant T cells, with clinical tolerability from the Company’s Phase 1 clinical trials of CUE-101 and CUE-102. In addition, the event will feature a review of the CUE-400 series, including new preclinical proof-of-concept data for lead candidate, CUE-401, aimed at transforming the standard of care for autoimmune diseases and inflammation. Cue Biopharma will also provide an overview of the CUE-500 program, including CUE-501, recently partnered with Boehringer Ingelheim, engineered to leverage anti-viral killer T cells for autoimmune diseases and cancer. The Company will also provide updates on its CUE-100 series clinical oncology programs.